1-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)-4-(cyclohexylmethylamino)butan-1-one | 1131992-59-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)-4-(cyclohexylmethylamino)butan-1-one
• 英文别名: 1-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]-4-(cyclohexylmethylamino)butan-1-one
• CAS: 1131992-59-0
• 化学式: C₂₈H₃₈ClN₃O
• 分子量: 468.082
• InChiKey: FBBLRLYJWSSKRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-amino-1-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)butan-1-one 、 环己烷基甲醛 在 三乙酰氧基硼氢化钠 、 三乙胺 作用下， 以 1,2-二氯乙烷 为溶剂， 以20%的产率得到1-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)-4-(cyclohexylmethylamino)butan-1-one
  参考文献：
  名称：

  Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity

  摘要：

  Novel diphenylpiperazine derivatives were synthesized and evaluated for their inhibitory activity against T-type calcium channel by whole-cell patch clamp recordings on HEK293 cells. Among the test compounds, 2 and 3d were effective in decreasing the response to formalin in both the first and second phases and demonstrated antiallodynic effects in a rat model of neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.06.082

文献信息

• USES, COMPOSITIONS AND METHODS
  申请人：Fisahn Andre

  公开号：US20210038589A1

  公开（公告）日：2021-02-11

  The present invention relates generally to calcium channel inhibitors for use in treating and/or preventing an amyloid disease of the nervous system. The invention also relates to related pharmaceutical compositions, kits and screening methods.
• T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF
  申请人：Praxis Precision Medicines, inc.

  公开号：US20210128537A1

  公开（公告）日：2021-05-06

  Described herein are compounds useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy) and mood disorders. The present invention further comprises methods for modulating the function of a T-type calcium channel.
• [EN] NOVEL COMPOUNDS, PROCESS FOR PREPARING THE SAME, AND COMPOSITION COMPRISING THE SAME FOR INHIBITING PAIN<br/>[FR] NOUVEAUX COMPOSÉS, PROCÉDÉ DE PRÉPARATION DE CEUX-CI ET COMPOSITION CONTENANT CEUX-CI DESTINÉE À INHIBER LA DOULEUR
  申请人：UNIV EWHA IND COLLABORATION

  公开号：WO2009035307A2

  公开（公告）日：2009-03-19

  The present invention relates to novel compounds, a process for preparing the same, and a pain relief composition, comprising the same. The compound of the present invention has excellent inhibitory effect on T-type calcium channel activity, and chronic neuropathic and inflammatory pain, thereby being used to relieve pain.
• [EN] T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS DE CANAL CALCIQUE DE TYPE T ET LEURS PROCÉDÉS D'UTILISATION
  申请人：PRAXIS PREC MEDICINES INC

  公开号：WO2018118101A1

  公开（公告）日：2018-06-28

  Described herein are compounds useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy) and mood disorders. The present invention further comprises methods for modulating the function of a T-type calcium channel.
• Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity
  作者：Yoo Lim Kam、Hee-Kyung Rhee、Hyewhon Rhim、Seung Keun Back、Heung Sik Na、Hea-Young Park Choo

  DOI：10.1016/j.bmc.2010.06.082

  日期：2010.8

  Novel diphenylpiperazine derivatives were synthesized and evaluated for their inhibitory activity against T-type calcium channel by whole-cell patch clamp recordings on HEK293 cells. Among the test compounds, 2 and 3d were effective in decreasing the response to formalin in both the first and second phases and demonstrated antiallodynic effects in a rat model of neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.